Last Update 10 Jan 26

Fair value Decreased 1.33%

CERT: Biosimulation Expansion And New CEO Should Support Shares Rebound

Analysts have trimmed their average price target on Certara by about $0.17 to roughly $12.38. This reflects recent cuts to some individual targets alongside continued recognition of the company as a leader in biosimulation and expectations that prior stock weakness tied to bookings, biopharma budget timing, and leadership changes may have been overdone.

Analyst Commentary

Recent research coverage reflects a divided but active view on Certara, with several firms updating ratings and price targets in a relatively tight range around current levels. Analysts are weighing the company’s position in biosimulation against recent execution issues in services and broader questions around valuation and competition.

Bullish Takeaways

Bullish analysts highlight Certara’s role as a leader in biosimulation, pointing to its broad market exposure and potential to support drug discovery and reduce early stage clinical work, which they see as a key part of the long term growth story.
Some upgrades argue that the prior selloff tied to softer Q3 services bookings, biopharma budget delays, and the CEO change went too far. They suggest the market reaction may not fully line up with what they view as a durable growth engine.
The acquisition of Chemaxon is viewed as a way to deepen Certara’s reach in discovery and preclinical workflows. Bullish analysts see this as important for expanding the company’s addressable opportunity and supporting revenue diversification.
One new Buy initiation with a US$10 target, alongside another Outperform rating with a US$13 target, indicates that a group of analysts see sufficient upside to justify positive recommendations even after recent volatility.

Bearish Takeaways

Bearish analysts and those on the sidelines are focused on execution risk, pointing to revised guidance following a slowdown in services bookings and expressing a preference to see clearer traction before taking a more positive stance.
Price target cuts to about US$12 from US$13 by multiple firms underscore concerns that valuation may already reflect a good portion of the biosimulation story, especially with competition and regulatory factors weighing on sector multiples.
Some neutral ratings, paired with price targets around US$9 to US$12, indicate that not all analysts are convinced near term growth will be strong enough to materially change the risk reward balance without better evidence of momentum.
Comments about competition and regulatory impacts point to potential pressure on valuation multiples, with cautious analysts watching to see whether Certara can convert its technology leadership into consistent, visible execution on bookings and guidance.

What's in the News

Certara announced that Jon Resnick will become Chief Executive Officer on January 1, 2026, succeeding Dr. William F. Feehery, whose departure will be treated as a termination without cause under his existing employment agreement (Executive Changes).
The company reported completion of a share repurchase program covering 3,023,677 shares, representing 1.88% of shares, for a total of US$37.08 million, including 1,230,398 shares, or 0.77%, bought for US$13.65 million between July 1 and September 30, 2025 (Buyback Tranche Update).
Certara issued earnings guidance for 2025, indicating expected revenue in the range of US$415m to US$420m (Corporate Guidance).
The company launched TFL Studio, a cloud native module within Phoenix Cloud designed to help PK and PD scientists create regulatory grade tables, figures, and listings with more automation, template reuse, and integration with its Integral data repository, with an AI PK Reports module to follow (Product Announcement).
Certara introduced Certara IQ, an AI powered Quantitative Systems Pharmacology solution that provides pre built models, a high performance simulation engine, and a no code interface for what if analysis to support drug discovery and development workflows (Product Announcement).

Valuation Changes

Fair Value: trimmed slightly from US$12.54 to about US$12.38, indicating a modest reset in the modeled estimate.
Discount Rate: adjusted marginally from 8.78% to about 8.77%, reflecting a very small change in the risk assumption used in the model.
Revenue Growth: eased from roughly 7.39% to about 7.09%, pointing to a slightly lower projected top line growth rate in the framework provided.
Net Profit Margin: moved from about 6.41% to roughly 6.33%, suggesting a small reduction in expected profitability levels.
Future P/E: shifted slightly higher from about 75.38x to roughly 75.98x, implying a modest increase in the earnings multiple used in the forward view.

Regulatory approvals and industry trends are boosting demand for Certara's biosimulation platforms, expanding its market and supporting stronger revenue streams.
Product innovation, strategic acquisitions, and cloud-based SaaS models increase customer retention, cross-selling, and margins, enhancing long-term profitability and earnings stability.
Certara's growth and profitability face risks from slow pharma adoption, reliance on large customers, rising costs, regulatory uncertainty, and possible delays in achieving returns from technology investments.

Catalysts

About Certara

Provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The recent qualification of Certara's Simcyp platform by the European Medicines Agency sets it apart as the only PBPK modeling tool with such approval, likely to increase customer adoption among global pharma companies seeking regulatory certainty and speed for their drug approvals, supporting future revenue growth.
Strong industry and regulatory momentum-such as the FDA's guidance to phase out animal testing in monoclonal antibody development-are rapidly increasing the need for biosimulation and model-informed drug development, expanding Certara's addressable market and driving sustained demand, positively impacting both revenues and bookings.
The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning, providing differentiated capabilities that democratize access and increase the potential customer base, which should translate to higher recurring revenue and margin expansion through cloud-based SaaS models.
Integration of newly acquired businesses (like Applied BioMath and Formedix), combined with more robust cross-selling between consulting and software offerings, positions Certara to drive higher deal sizes and improve operating leverage, which strengthens both net margins and operating income over time.
Investment in cloud-based delivery and ongoing product innovation (as shown with updates to Phoenix and Pinnacle21 suites) further enhances customer stickiness and predictability of subscription revenue, supporting gross margin stability and long-term earnings growth.

Certara Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Certara's revenue will grow by 8.6% annually over the next 3 years.
Analysts assume that profit margins will shrink from 2.0% today to 1.4% in 3 years time.
Analysts expect earnings to reach $7.4 million (and earnings per share of $0.04) by about September 2028, down from $8.0 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 385.3x on those 2028 earnings, up from 211.3x today. This future PE is greater than the current PE for the US Healthcare Services industry at 54.8x.
Analysts expect the number of shares outstanding to decline by 0.22% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.27%, as per the Simply Wall St company report.

Certara Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The company faces potential headwinds from pharmaceutical industry cost containment, large pharma customer caution, and increased geopolitical and macroeconomic uncertainty-factors (including proposed tariffs and new pricing algorithms) that could delay decision-making and depress R&D budgets, which would negatively impact Certara's revenue and bookings growth in the long term.
Certara's R&D and operational spending has been increasing, with significant discretionary investments in software development, AI, and new product launches, and with the integration of multiple recent acquisitions. If these investments fail to generate expected adoption or ROI, operating expenses and margin pressure could undermine net earnings and profitability.
The company's continued growth depends heavily on adoption of new technologies (AI-enabled platforms, next-generation QSP products, etc.) and regulatory acceptance; any delays, low market uptake, or challenges in convincing regulators to integrate AI with model-informed drug development could slow software growth and diminish future revenues.
Although there is optimism about the multibillion-dollar addressable market for biosimulation (especially due to moves like the FDA's push to phase out animal testing), the adoption curve in pharma is often slow and complex, with many customers only piloting or cautiously expanding platform use-if customer education, regulatory clarity, or adoption stalls, bookings and revenue growth may not materialize as quickly as projected, affecting long-term earnings.
Certara's top-line and financial performance remains exposed to customer tier concentration; softness or timing issues from large Tier 1 customers can cause significant volatility in bookings and renewal cycles, making revenue less predictable and increasing risk to both revenue consistency and operating margins if consolidation or budget reductions occur among top clients.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $14.111 for Certara based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $16.0, and the most bearish reporting a price target of just $11.5.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $519.5 million, earnings will come to $7.4 million, and it would be trading on a PE ratio of 385.3x, assuming you use a discount rate of 8.3%.
Given the current share price of $10.5, the analyst price target of $14.11 is 25.6% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Certara?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Maintain Certara Price Target as Pharma Sector Recovery and New Developments Drive Outlook